Month: November 2024

The 2024 CACA Integrated Lung Cancer Conference, hosted by the Chinese Anti-Cancer Association and the Chinese Anti-Cancer Association’s Integrated Lung Cancer Committee (under preparation), was held in Zhuhai on October 25–26, 2024. With the theme “Uniting Efforts, Leading the Future,” the conference gathered leading domestic experts and scholars in the field of pulmonary tumors for in-depth and broad academic exchanges on hot and challenging topics related to lung cancer. During the conference, Oncology Frontier invited Dr. Gen Lin from the Cancer Center of Beijing Chest Hospital, Capital Medical University, for an exclusive interview. Professor Lin shared insights into the current clinical practice of immunotherapy for non-small cell lung cancer (NSCLC) and progress in strategies to address secondary resistance in immunotherapy.

The 2024 CACA Integrated Lung Cancer Conference, hosted by the Chinese Anti-Cancer Association, was held in Zhuhai from October 25 to 26. Focusing on the theme “Gathering Strength, Leading the Future,” the conference brought together prominent experts in the field of lung cancer to discuss critical issues and advancements. Oncology frontier interviewed Dr. Weimin Li from West China Hospital, Sichuan University, who shared insights on the progress and future outlook of precision lung cancer screening in China.

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting has successfully concluded, showcasing groundbreaking oncology research. Dr. Chang Liu from Professor Lin Shen’s team at Peking University Cancer Hospital presented their study on the efficacy and safety of CCR8 monoclonal antibody LM-108 combined with PD-1 antibody in gastric cancer patients. Professor Shen’s presentation at ASCO sparked significant industry interest. Oncology Frontier invited Dr. Chang Liu to provide an in-depth analysis of this study’s breakthroughs and significance.

Led by the Chinese Anti-Cancer Association (CACA), top oncology experts across various fields collaborated over a year to develop China’s first integrated oncology guideline, the CACA Integrated Cancer Diagnosis and Treatment Guideline, which was published in 2022. As part of a national educational tour on the guideline, Dr. Ye Wei from Huadong Hospital Affiliated to Fudan University recently shared insights with Oncology Frontier on the clinical impact of the CACA guideline for colorectal cancer (CRC).

The 9th Academic Symposium of the Chinese Branch of the International Hepato-Pancreato-Biliary Association (IHPBA) was held in Wuhan from October 25-27, 2024, drawing renowned experts from over 20 countries, including the United States, Germany, France, Russia, and Australia. With more than 50 prominent international scholars, 21 academicians, and over 700 experts in liver, gallbladder, and pancreas oncology, the symposium provided a platform to discuss the latest advancements and standards in liver cancer diagnosis and treatment. Dr. Tianqiang Song from Tianjin Medical University Cancer Institute and Hospital delivered an insightful presentation on “Advancements in Perioperative Treatments for Liver Cancer and the Tianjin Experience.” In a joint interview with Oncology Frontier, Professor Song shared insights into perioperative treatment research and practical experiences.

The 2024 CACA Integrated Lung Cancer Conference, organized by the Chinese Anti-Cancer Association and the CACA Lung Cancer Integration Committee, was held in Zhuhai from October 25 to 26. Under the theme “Gathering Strength and Leading the Future,” the conference brought together top experts in lung cancer to discuss key challenges and advancements. Oncology Frontier interviewed Prof. Li Zhang from Sun Yat-sen University Cancer Center, who shared insights on the clinical applications, development, and future prospects of antibody-drug conjugates (ADCs) in lung cancer treatment.

From October 17 to 19, 2024, the 18th National Breast Cancer Conference and the 19th Shanghai International Breast Cancer Symposium (SIBCS 2024) took place in Shanghai. During this period, the fourth Controversy & Consensus Consortium (3C) Summit, focusing on clinical practice in Chinese breast cancer, was successfully held. Leading breast cancer experts and patient representatives participated in discussions and voting on updates for the 2025 CBCS Guidelines “Little Red Book.”

The 9th Congress of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (CCIHPBA) and The Seminar on the Academic Thoughts of Prof. Oiu Fazu and his 110 Birth Anniversary and Sino -Geman Medical Educaton Fomum, along with A Commemorative Ceremony in honor of the late Prof. Wan Yee Joseph LAU, were held in Wuhan from October 24 to 27, 2024. Upholding the themes of "Exchange, Standardization, Innovation, and Development," the event brought together renowned hepato-pancreato-biliary surgery experts from home and abroad to discuss key challenges, share clinical insights, and promote new techniques. At the symposium, Prof. Kuansheng Ma from The Southwest Hospital of Army Medical University, delivered an academic presentation titled, “Interpretation of the Primary Liver Cancer Diagnosis and Treatment Guidelines (2024 Edition) - Systemic Treatment.” In this exclusive interview, Prof. Ma shares further insights on this topic.